Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 2/2014

01-04-2014 | Original Article

Idiopathic pulmonary fibrosis as a prognostic factor in non-small cell lung cancer

Authors: Taichiro Goto, Arafumi Maeshima, Yoshitaka Oyamada, Ryoichi Kato

Published in: International Journal of Clinical Oncology | Issue 2/2014

Login to get access

Abstract

Background

We investigated the postoperative mortality and long-term survival of lung cancer patients with underlying idiopathic pulmonary fibrosis (IPF).

Methods

The data of 387 primary lung cancer patients treated by surgical resection at our hospital between 1995 and 2008 were retrospectively reviewed. Clinicopathological characteristics such as age, gender, survival, presence/absence of underlying IPF, atypical adenomatous hyperplasia (AAH), and the associations among these factors were examined.

Results

Among the 387 patients, 65 (16.8 %) had underlying IPF as detected by histopathology of the resected specimen (IPF group). The percentages of men and squamous cell carcinomas were significantly higher in the IPF group. None of our patients showed concomitant presence of AAH and IPF. Four of the 65 patients showed acute exacerbation of the IPF postoperatively, and all 4 of these patients died in hospital. In patients with non-small cell lung carcinoma, the postoperative survival tended to be lower in the IPF group than in the non-IPF group. Analysis using a Cox proportional hazards model by disease stage revealed that presence of underlying IPF was a risk factor for postoperative mortality in patients with pathological stage I/II but not for stage III/IV. Respiratory failure was the second main cause of death in the stage I/II lung cancer patients of the IPF group.

Conclusion

Histopathological evidence of IPF was a risk factor for postoperative mortality and poor long-term survival, especially in patients with stage I/II non-small cell lung cancer, with postoperative respiratory failure representing the major cause of death.
Literature
1.
Katzenstein AL, Myers JL (1998) Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 157:1301–1315PubMedCrossRef
2.
Kawabata Y, Fukushima K, Uchiyama T et al (2001) A focal usual interstitial pneumonia lesion: an important risk factor in diffuse alveolar damage–acute exacerbation of a focal usual interstitial pneumonia patient. Nihon Kokyuki Gakkai Zasshi 39:316–321PubMed
3.
King TE Jr, Schwarz MI, Brown K et al (2001) Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med 164:1025–1032PubMedCrossRef
4.
Reynolds HY (1998) Diagnostic and management strategies for diffuse interstitial lung disease. Chest 113:192–202PubMedCrossRef
5.
Riha RL, Duhig EE, Clarke BE et al (2002) Survival of patients with biopsy-proven usual interstitial pneumonia and nonspecific interstitial pneumonia. Eur Respir J 19:1114–1118PubMedCrossRef
6.
Bouros D, Hatzakis K, Labrakis H et al (2002) Association of malignancy with diseases causing interstitial pulmonary changes. Chest 121:1278–1289PubMedCrossRef
7.
Hubbard R, Venn A, Lewis S et al (2000) Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med 161:5–8PubMedCrossRef
8.
Park J, Kim DS, Shim TS et al (2001) Lung cancer in patients with idiopathic pulmonary fibrosis. Eur Respir J 17:1216–1219PubMedCrossRef
9.
10.
Sobin LH, Gospodarowicz MK, Wittekind C (2009) TNM classification of malignant tumors, 7th edn. Wiley-Blackwell, New York
11.
Raghu G, Collard HR, Egan JJ et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788–824PubMedCrossRef
12.
Mori M, Chiba R, Takahashi T (1993) Atypical adenomatous hyperplasia of the lung and its differentiation from adenocarcinoma. Characterization of atypical cells by morphometry and multivariate cluster analysis. Cancer (Phila) 72:2331–2340CrossRef
13.
Goto T, Maeshima A, Akanabe K et al (2011) Acute exacerbation of idiopathic pulmonary fibrosis of microscopic usual interstitial pneumonia pattern after lung cancer surgery. Ann Thorac Cardiovasc Surg 17:573–576PubMedCrossRef
14.
Chiyo M, Sekine Y, Iwata T et al (2003) Impact of interstitial lung disease on surgical morbidity and mortality for lung cancer: analyses of short-term and long-term outcomes. J Thorac Cardiovasc Surg 126:1141–1146PubMedCrossRef
15.
Kumar P, Goldstraw P, Yamada K et al (2003) Pulmonary fibrosis and lung cancer: risk and benefit analysis of pulmonary resection. J Thorac Cardiovasc Surg 125:1321–1327PubMedCrossRef
16.
Kawasaki H, Nagai K, Yoshida J et al (2002) Postoperative morbidity, mortality, and survival in lung cancer associated with idiopathic pulmonary fibrosis. J Surg Oncol 81:33–37PubMedCrossRef
17.
Kutlu CA, Williams EA, Evans TW et al (2000) Acute lung injury and acute respiratory distress syndrome after pulmonary resection. Ann Thorac Surg 69:376–380PubMedCrossRef
18.
Watanabe A, Higami T, Ohori S, et al (2008) Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis? J Thorac Cardiovasc Surg 136:1357–1363, 1363.e1–2
19.
Martinod E, Azorin JF, Sadoun D et al (2002) Surgical resection of lung cancer in patients with underlying interstitial lung disease. Ann Thorac Surg 74:1004–1007PubMedCrossRef
20.
Okamoto T, Gotoh M, Masuya D et al (2004) Clinical analysis of interstitial pneumonia after surgery for lung cancer. Jpn J Thorac Cardiovasc Surg 52:323–329PubMedCrossRef
21.
Utz JP, Ryu JH, Douglas WW et al (2001) High short-term mortality following lung biopsy for usual interstitial pneumonia. Eur Respir J 17:175–179PubMedCrossRef
22.
Koizumi K, Hirata T, Hirai K et al (2004) Surgical treatment of lung cancer combined with interstitial pneumonia: the effect of surgical approach on postoperative acute exacerbation. Ann Thorac Cardiovasc Surg 10:340–346PubMed
23.
Fujimoto T, Okazaki T, Matsukura T, et al (2003) Operation for lung cancer in patients with idiopathic pulmonary fibrosis: surgical contraindication? Ann Thorac Surg 76:1674–1678 (discussion 1679)
24.
Takeuchi E, Yamaguchi T, Mori M et al (1996) Characteristics and management of patients with lung cancer and idiopathic interstitial pneumonia. Nihon Kyobu Shikkan Gakkai Zasshi 34:653–658PubMed
25.
Hanley ME, King TE Jr, Schwarz MI et al (1991) The impact of smoking on mechanical properties of the lungs in idiopathic pulmonary fibrosis and sarcoidosis. Am Rev Respir Dis 144:1102–1106PubMedCrossRef
26.
Logan PM, Miller RR, Evans K et al (1996) Bronchogenic carcinoma and coexistent bronchioloalveolar cell adenomas. Assessment of radiologic detection and follow-up in 28 patients. Chest 109:713–717PubMedCrossRef
27.
Suzuki K, Nagai K, Yoshida J et al (1997) The prognosis of resected lung carcinoma associated with atypical adenomatous hyperplasia: a comparison of the prognosis of well-differentiated adenocarcinoma associated with atypical adenomatous hyperplasia and intrapulmonary metastasis. Cancer (Phila) 79:1521–1526CrossRef
28.
Matsushita H, Tanaka S, Saiki Y et al (1995) Lung cancer associated with usual interstitial pneumonia. Pathol Int 45:925–932PubMedCrossRef
29.
Mizushima Y, Kobayashi M (1995) Clinical characteristics of synchronous multiple lung cancer associated with idiopathic pulmonary fibrosis. A review of Japanese cases. Chest 108:1272–1277PubMedCrossRef
30.
31.
Portillo K, Morera J (2012) Combined pulmonary fibrosis and emphysema syndrome: a new phenotype within the spectrum of smoking-related interstitial lung disease. Pulm Med 2012:867870PubMedCentralPubMedCrossRef
Metadata
Title
Idiopathic pulmonary fibrosis as a prognostic factor in non-small cell lung cancer
Authors
Taichiro Goto
Arafumi Maeshima
Yoshitaka Oyamada
Ryoichi Kato
Publication date
01-04-2014
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 2/2014
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-013-0566-1

Other articles of this Issue 2/2014

International Journal of Clinical Oncology 2/2014 Go to the issue

Original Article

Pathological outcomes of Japanese men eligible for active surveillance after radical prostatectomy

Original Article

Usefulness of one-point plasma SN-38G/SN-38 concentration ratios as a substitute for UGT1A1 genetic information after irinotecan administration

Original Article

Curcumin targets the AKT–mTOR pathway for uterine leiomyosarcoma tumor growth suppression

Original Article

Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials

Review Article

Is biomarker research advancing in the era of personalized medicine for head and neck cancer?

Original Article

Clinicopathological correlation for the role of fluorodeoxyglucose positron emission tomography computed tomography in detection of choroidal malignant melanoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits